Where Globus Medical Stands With Analysts
Portfolio Pulse from Benzinga Insights
Over the past three months, 8 analysts have shared their insights on Globus Medical (NYSE:GMED), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $72.0 from $65.50. Analysts have raised their price targets and ratings, reflecting positive sentiment towards the company's future performance.
July 15, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have shown a positive sentiment towards Globus Medical (NYSE:GMED) over the past three months, with an increased average 12-month price target of $72.0. This reflects a bullish outlook on the company's future performance.
The increase in the average 12-month price target from $65.50 to $72.0, along with multiple analysts raising their ratings and price targets, indicates a strong positive sentiment towards Globus Medical. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100